

EXHIBIT A

Patterson Belknap Webb & Tyler LLP

1133 Avenue of the Americas New York, NY 10036-6710 212.336.2000 fax 212.336.2222 www.pbwt.com

From: Chad J. Peterman
Phone: (212) 336-2877
Direct Fax: (212) 336-7914

Date: June 30, 2006
Client/Matter #: A0407-1621
of Pages (incl. cover): 4

Please deliver as soon as possible to:

Recipient	Firm Name	Fax	Phone
Christopher T. Holding	Goodwin Procter LLP	(617) 523-1231	(617) 570-1679
Asim Bhansali	Keker & Van Nest, LLP	(415) 397-7188	(415) 391-5400
Adam Steinfeld	Garwin, Gerstein, & Fisher, L.L.P.	(212) 764-6620 ✓	(212) 398-0053
Joseph T. Lukens	Hangley Aronchick Segal & Pudlin	(215) 568-0300	(215) 496-7032
Steve Shadowen	Hangley Aronchick Segal & Pudlin	(717) 364-1020	(717) 364-1010
Scott E. Perwin	Kenny Nachwalter P.A.	(305) 372-1861	(305) 373-1000
John W. Turner	Susman Godfrey LLP	(214) 754-1933 ✓	(214) 754-1914
Kenneth Zylstra	Schiffrin & Barroway, L.L.P.	(610) 667-7056	(610) 822-0276
Casey Murphy	Schiffrin & Barroway, L.L.P.	(610) 667-7056	(610) 667-7706
Mary B. Graham	Morris, Nichols, Arslit & Tunnell	(302) 658-3989	(302) 351-9287
Steven C. Sunshine	Cadwalader, Wickersham & Taft LLP	(202) 862-2400	(202) 862-2329;
Matthew P. Hendrickson	Cadwalader, Wickersham & Taft LLP	(212) 504-6666	(212) 504-5792
Timothy Bickham	Steptoe & Johnson	(202) 429-3902	(202) 429-5517

Message:

Please see the attached

CONFIDENTIALITY NOTE: This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and destroy the transmission. Thank you.

IRS Circular 230 disclosure: Any tax advice contained in this communication (including any attachments or enclosures) was not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed in this communication. (The foregoing disclaimer has been affixed pursuant to U.S. Treasury regulations governing tax practitioners.)

Patterson Belknap Webb & Tyler LLP

1133 Avenue of the Americas New York, NY 10036-6710 212 336 2000 fax 212 336 2222 www.pbwt.com

June 30, 2006

Chad J. Peterman
(212) 336-2877
Direct Fax (212) 336-7914
cjpeterman@pbwt.com

By Fax

Christopher T. Holding, Esq.
Goodwin Procter LLP
Exchange Place
53 State Street
Boston, MA 02109-1881Re: In Re TriCor Antitrust Litigation

Dear Chris:

I write on behalf of Abbott and Fournier in response to your June 23, 2006 letter. We disagree with the sweeping characterizations in your letter, but do not believe that a point-by-point response is required or productive. However, we provide the following responses to specific points you raise. In providing our responses, we do not waive any of our prior general and specific objections to the Interrogatories and are agreeing to supplement our prior answers to avoid unnecessary motion practice.

Interrogatory No. 5

Given the restrictions that you added, Abbott and Fournier will supplement their answers to this Interrogatory by July 11, 2006.

Interrogatory Nos. 6 and 7

Abbott and Fournier will provide a supplemental response to Interrogatory Nos. 6 and 7 that comports with Fed. R. Civ. P. 33(d) by July 31, 2006. Your proposal of July 11, 2006 is not an adequate amount of time. We will take your interpretation of Rule 33(d) under advisement in formulating our response but do not agree to your overly broad and burdensome interpretation of that rule's requirements. We continue to reserve the right to supplement our responses to these Interrogatories and any other discovery request as appropriate.

As discussed we will search for responsive documents concerning the Hilleman study. If there are responsive documents relating to the publication referenced in Abbott TriCor 95944, we will produce them.

Christopher T. Holding, Esq.
June 30, 2006
Page 2

Interrogatory Nos. 1 and 3


We confirm that there are no non-privileged tests on Teva's product performed by or on behalf of Abbott and Fournier other than the tests identified in Dr. Byrn's reports and the tests conducted by his laboratory in connection with those reports. Documents concerning those tests were produced in the patent litigation.

Plaintiffs agree that our pre-suit investigation regarding Teva's infringement is privileged. Any documents, communications and other activities created or occurring pre-suit would have been done under the direction of outside litigation counsel or pursuant to instruction of outside counsel, thereby reflecting communications to and from outside litigation counsel. Pursuant to the practice and working agreement of this case, and federal litigation practice in general, we are not going to log communications or activities reflecting communications to and from outside litigation counsel. Thus, we will not supplement our response as you requested.

You have asked us to make a binding election as to whether Abbott and Fournier will waive reliance on any tests of Teva's product subject to a privilege claim. We agree to an election in concept, but maintain that July 11, 2006 is premature. We propose to make an election 30-days prior to the close of fact discovery. If Abbott or Fournier elect to waive privilege, we will make discovery available immediately. Our proposal is subject to an agreement by all antitrust claimants to notify us by the same date whether they intend to assert privilege as to any tests conducted on Teva's products and, if so, make discovery available immediately.

I have attempted to address the main issues that you raised in the letter, but have not responded to each individual point. My decision not to address particular points should not be construed as an agreement with Teva on those points.

Sincerely,



Chad J. Peterman

cc: Asim Bhansali, Esq.
Adam Steinfeld, Esq.
Joseph T. Lukens, Esq.
Steve Shadowen, Esq.
Scott E. Perwin, Esq.
John W. Turner, Esq.
Kenneth Zylstra, Esq.

Christopher T. Holding, Esq.

June 30, 2006

Page 3

Casey Murphy, Esq.

Mary B. Graham, Esq.

Steven Sunshine, Esq.

Matthew Hendrickson, Esq.

Timothy C. Bickham, Esq.